
    
      This clinical trial is to evaluate the effect of bone metabolism and blood sugar of
      evogliptin and dapagliflozin in the menopause female patients with osteopenia and type 2
      diabetes.

      Bone metabolism (bone markers and bone density) and blood sugar (AGE and glucose variability)
      after 12 weeks and 48 weeks will be evaluated.

      This clinical trial conducts in two arms, and each arm recruits 60 subjects. If a subject
      voluntarily agrees to participate and meets the inclusion and exclusion criteria for the
      clinical trial, the subject will be randomly assigned to one of the two arms.

      The total period after the subject enrollment is 48 weeks, and a total of six visits are made
      with screening, baseline, 12 weeks, 24 weeks, 36 weeks, and 48 weeks.

      Efficacy evaluation will be carried out changes on blood sugar, bone markers and density and
      after 12 and 48 weeks.

      The results of this study are intended to be a reference to future clinical trials.
    
  